24188-74-7Relevant articles and documents
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection
Scola, Paul M.,Sun, Li-Qiang,Wang, Alan Xiangdong,Chen, Jie,Sin, Ny,Venables, Brian L.,Sit, Sing-Yuen,Chen, Yan,Cocuzza, Anthony,Bilder, Donna M.,D'Andrea, Stanley V.,Zheng, Barbara,Hewawasam, Piyasena,Tu, Yong,Friborg, Jacques,Falk, Paul,Hernandez, Dennis,Levine, Steven,Chen, Chaoqun,Yu, Fei,Sheaffer, Amy K.,Zhai, Guangzhi,Barry, Diana,Knipe, Jay O.,Han, Yong-Hae,Schartman, Richard,Donoso, Maria,Mosure, Kathy,Sinz, Michael W.,Zvyaga, Tatyana,Good, Andrew C.,Rajamani, Ramkumar,Kish, Kevin,Tredup, Jeffrey,Klei, Herbert E.,Gao, Qi,Mueller, Luciano,Colonno, Richard J.,Grasela, Dennis M.,Adams, Stephen P.,Loy, James,Levesque, Paul C.,Sun, Huabin,Shi, Hong,Sun, Lucy,Warner, William,Li, Danshi,Zhu, Jialong,Meanwell, Nicholas A.,McPhee, Fiona
, p. 1730 - 1752 (2014)
The discovery of asunaprevir (BMS-650032, 24) is described. This tripeptidic acylsulfonamide inhibitor of the NS3/4A enzyme is currently in phase III clinical trials for the treatment of hepatitis C virus infection. The discovery of 24 was enabled by employing an isolated rabbit heart model to screen for the cardiovascular (CV) liabilities (changes to HR and SNRT) that were responsible for the discontinuation of an earlier lead from this chemical series, BMS-605339 (1), from clinical trials. The structure-activity relationships (SARs) developed with respect to CV effects established that small structural changes to the P2* subsite of the molecule had a significant impact on the CV profile of a given compound. The antiviral activity, preclincial PK profile, and toxicology studies in rat and dog supported clinical development of BMS-650032 (24).
GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
-
Paragraph 00950; 00951, (2021/01/22)
Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
Process for Synthesizing Substituted Isoquinolines
-
Page/Page column 6, (2010/04/23)
The present disclosure generally relates to a process for synthesizing optionally substituted 1-chloro-4-methoxyisoquinolines. The present disclosure also relates to intermediates useful in this process.